Umbralisib (TGR-1202) | PI3Kδ/CK1ε Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1532533-67-7
Formula :	C₃₁H₂₄F₃N₅O₃
M.W :	571.55
SMILES Code :	O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=C1C=C(F)C=C6
Synonyms :	TGR-1202; RP-5264; RP5264
MDL No. :	MFCD28386165
InChI Key :	IUVCFHHAEHNCFT-INIZCTEOSA-N
Pubchem ID :	72950888

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Daudi cells	1 µM	24 hours	To evaluate the effect of Umbralisib in combination with the anti-CD20 antibody ublituximab on ADCC and ADCP activities in B-cell lymphoma cells. Results showed that the U2 combination (ublituximab + umbralisib) significantly enhanced ADCC and ADCP activities.	PMC10160608
Raji cells	1 µM	24 hours	To evaluate the effect of Umbralisib in combination with the anti-CD20 antibody ublituximab on ADCC and ADCP activities in B-cell lymphoma cells. Results showed that the U2 combination (ublituximab + umbralisib) significantly enhanced ADCC and ADCP activities.	PMC10160608
CLL patient T cells	1 μM	72 hours	To evaluate the effects of PI3K inhibitors on T cells from CLL patients. Results showed that Umbralisib better maintained Treg numbers and expression of immunosuppressive markers compared to idelalisib and duvelisib.	PMC7362385
Normal human T cells	0.1 to 10 μM	24 hours	To evaluate the effects of PI3K inhibitors on T cell survival and function. Results showed that Umbralisib did not affect T cell survival at concentrations of 0.1 to 10 μM and better maintained Treg numbers and function compared to idelalisib and duvelisib.	PMC7362385
Murine splenocytes	1 µM	6 hours	To evaluate the effect of Umbralisib on murine T-cell activation, results showed that Umbralisib reduced CD69 expression in CD4+ and CD8+ T cells.	PMC9949793
Human PBMCs	1 µM	72 hours		PMC9949793
Human PBMCs	1 µM	6 hours		PMC9949793
Human CAR T cells	10 μM	2 weeks	To test if PI3K inhibitors could augment CAR T cell phenotype and cytotoxicity, found that PI3K δ-inhibited CARs lysed human tumors in vitro more effectively than PI3K γ-expanded or traditionally expanded CAR T cells	PMC7496332
THP-1 cells	10 μM	72 hours	Assess migration capability of THP-1 cells	PMC9059134
MV-4-11 cells	5.7 μM	72 hours	Degradation of PBRM1	PMC9059134
Pmel-1 CD8+T cells	10 μM	1 week	To test how blockade of either PI3K γand/or PI3K δcatalytic subunits impacts T cell immunity, found that IPI-145 (dual inhibitor) generated the least therapeutic cell product	PMC7496332
Chronic lymphocytic leukemia cells	1 nM - 10000 nM	72 hours	To evaluate the inhibitory effect of BOC-D-FMK on CFZ-induced apoptosis. Results showed that BOC-D-FMK significantly reduced CFZ-induced PARP cleavage and apoptosis.	PMC9588626
CMML patient bone marrow mononuclear cells	0.3-14 μM	72 hours	Evaluate the growth inhibitory effect of Umbralisib on CMML patient bone marrow mononuclear cells, showing GI50 values between 0.3-14 μM in most samples.	PMC9059134

NSG mice	Burkitt lymphoma xenograft model	Oral	150 mg/kg	Twice daily for 17 days	To evaluate the antitumor effect of Umbralisib in combination with the anti-CD20 antibody ublituximab in a Burkitt lymphoma xenograft model. Results showed that the U2 combination (ublituximab + umbralisib) significantly inhibited tumor growth.	PMC10160608
Mice	Em-TCL1 CLL model	Oral gavage	100 mg/kg	Once daily for 21 days	To evaluate the antitumor efficacy and immunomodulatory effects of Umbralisib in the CLL model. Results showed that Umbralisib effectively reduced tumor burden while better maintaining Treg numbers and function and reducing immune-mediated toxicity compared to idelalisib and duvelisib.	PMC7362385
Mice	TAPP1R218LxTAPP2R211L (TAPP KI) mouse model	Intraperitoneal injection	0.1mg/mouse	Twice daily for 4 weeks	To assess the impact of dual PI3Kδ and γ inhibition on autoantibody-mediated disease. Results showed significant reduction in CD86+ B cells, germinal center B cells, follicular helper T cells, and plasma cells, along with attenuation of abnormally elevated serum IgG isotypes. Treatment also significantly reduced IgM and IgG autoantibodies targeting nuclear antigens, matrix proteins, and other autoantigens, and improved kidney pathology.	PMC10206234
Sprague-Dawley (SD) rats	Rat plasma pharmacokinetic model	Oral	80 mg/kg	Single dose	To evaluate the effect of sophocarpine on the pharmacokinetics of umbralisib. Results showed that sophocarpine significantly reduced AUC0→∞ and Cmax of umbralisib and increased CLz/F.	PMC8811118

{[proInfo.proName]}

CAS No.: 1532533-67-7

{[proInfo.proName]}

CAS No.: 1532533-67-7

Alternative Products

Product Details of Umbralisib

Safety of Umbralisib

Related Pathways of Umbralisib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03178201	Follicular Lymphoma	PHASE2	TERMINATED	2020-06-30	Columbia University Medical Ce... More >>nter, New York, New York, 10019, United States Less <<
NCT03364231	Marginal Zone Lymphoma\|Waldens... More >>trom Macroglobulinemia\|Non Follicular Indolent Non-Hodgkin Lymphoma Less <<	PHASE2	COMPLETED	2022-02-15	TG Therapeutics Investigationa... More >>l Trial Site, Washington, District of Columbia, 20007, United States\|TG Therapeutics Investigational Trial Site, Boston, Massachusetts, 02215, United States\|TG Therapeutics Investigational Trial Site, Hackensack, New Jersey, 07601, United States\|TG Therapeutics Investigational Trial Site, New York, New York, 10065, United States Less <<
NCT02742090	Chronic Lymphocytic Leukemia	PHASE2	TERMINATED	2021-06-10	TG Therapeutics Investigationa... More >>l Trial Site, Huntsville, Alabama, 35805, United States\|TG Therapeutics Investigational Trial Site, Washington, District of Columbia, 20007, United States\|TG Therapeutics Investigational Trial Site, Fort Myers, Florida, 33916, United States\|TG Therapeutics Investigational Trial Site, Saint Petersburg, Florida, 33705, United States\|TG Therapeutics Investigational Trial Site, Kansas City, Missouri, 64132, United States\|TG Therapeutics Investigational Trial Site, Lebanon, New Hampshire, 03756, United States\|TG Therapeutics Investigational Trial Site, Hackensack, New Jersey, 07601, United States\|TG Therapeutics Investigational Trial Site, New Hyde Park, New York, 11042, United States\|TG Therapeutics Investigational Trial Site, New York, New York, 10032, United States\|TG Therapeutics Investigational Trial Site, Rochester, New York, 14642, United States\|TG Therapeutics Investigational Trial Site, Durham, North Carolina, 27710, United States\|TG Therapeutics Investigational Trial Site, Hershey, Pennsylvania, 17033, United States\|TG Therapeutics Investigational Trial Site, Philadelphia, Pennsylvania, 19146, United States\|TG Therapeutics Investigational Trial Site, Nashville, Tennessee, 37203, United States\|TG Therapeutics Investigational Trial Site, Seattle, Washington, 98104, United States Less <<
NCT01767766	Non-Hodgkin's Lymphoma\|Chronic... More >> Lymphocytic Leukemia\|Peripheral T-Cell Lymphoma\|Hodgkin's Lymphoma Less <<	PHASE1	COMPLETED	2025-02-18	TG Therapeutics Trial Site, Sa... More >>rasota, Florida, 34232, United States\|TG Therapeutics Trial Site, Hackensack, New Jersey, 07601, United States\|TG Therapeutics Trial Site, New York, New York, 10019, United States\|TG Therapeutics Trial Site, Durham, North Carolina, 27710, United States\|TG Therapeutics Trial Site, Cincinnati, Ohio, 45242, United States\|TG Therapeutics Trial Site, Nashville, Tennessee, 37203, United States\|TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, 53226, United States Less <<
NCT04163718	Chronic Lymphocytic Leukemia	PHASE2	TERMINATED	2022-10-19	H. Lee Moffitt Cancer Center &... More >> Research Institute, Tampa, Florida, 33612, United States Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed